A phase I open label, randomized, crossover study comparing bioavailability of MRX-5LBT (Lidocaine Patch 20%) and LIDODERM (Lidocaine Patch 5%, Endo Pharmaceuticals Inc.) in healthy adult subjects
Latest Information Update: 09 Aug 2023
At a glance
- Drugs Lidocaine (Primary)
- Indications Neuropathic pain
- Focus Pharmacokinetics
- 09 Aug 2023 According to MEDRx media release, company announced that USFDA accepted New Drug Application(NDA) for MRX-5LBT.
- 30 Nov 2016 New trial record